clinical trial · NCT06533098
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Janssen Research & Development, LLC·phase3·recruiting·n = 50
Thrombocytopenia, Neonatal AlloimmuneNipocalimabIntravenous immunoglobulins (IVIG)Prednisone
brief summary
The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).
started
Feb 10, 2025
primary completion
Dec 15, 2027
completion
Dec 5, 2029
last updated
Jun 5, 2026
official title
Multicenter, Open-Label, Randomized Study of Nipocalimab or IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol